MaxCell® is StemCyte's premium cord blood processing method that uses plasma depletion to preserve more total nucleated cells than conventional red-cell-depletion processing. MaxCell® stores the cord blood in a volume of up to 80 mL, compared with 25 mL for StandardCell® processing, retaining a larger usable cell yield for future transplantation. MaxCell® is offered by StemCyte, Inc., a global cord blood bank founded in 1997 in Baldwin Park, California, accredited by FACT and AABB, and the U.S. licensee of REGENECYTE® under FDA US License 2280.
Small beginnings. Maximum cells.
MaxCell® preserves up to 80 mL of cord blood vs. ~25 mL standard. About three times the volume, more of the cells used in engraftment.
How does MaxCell® preserve more cells?
Most cord blood banks reduce a unit to a concentrate, stripping out cells in the process. MaxCell® is StemCyte's proprietary processing method, engineered to preserve a higher recovery of total nucleated cells, keeping more of the cord blood that was there at birth.
Why does MaxCell® processing matter?
More cells, better odds
Total nucleated cell (TNC) count is a key predictor of engraftment success. Research has shown that higher TNC doses are associated with faster engraftment and better survival outcomes in cord blood transplants. MaxCell® processing preserves more TNCs than standard red blood cell depletion methods.
More options, later
A larger preserved unit gives future physicians flexibility. Some emerging cord blood therapies benefit from having a higher cell count or volume than a concentrated 25mL unit can provide. Preserving up to 80 mL of the original sample keeps more treatment pathways available, including applications not yet available.
Frequently asked questions
Start with more.
Plans with MaxCell® processing preserve about three times the volume of standard processing, for whatever treatment the future holds.
Build your plan